PSMD12-Mediated M1 Ubiquitination of Influenza A Virus at K102 Regulates Viral Replication

Xianfeng Hui1,2, Lei Cao1,2, Ting Xu1,2

  • 1State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural Universitygrid.35155.37, Wuhan, China.

Journal of Virology
|July 21, 2022
PubMed

Insights

Researchers identified PSMD12 as a host factor crucial for influenza A virus (IAV) replication. PSMD12 regulates M1 protein ubiquitination, impacting virus assembly, budding, and virulence, offering a potential antiviral target.

Area of Science:

  • Virology
  • Molecular Biology
  • Host-Pathogen Interactions

Background:

  • Influenza A virus (IAV) M1 protein is vital for virus assembly and budding.
  • Host factors are essential for IAV replication, making them targets for antiviral development.
  • Understanding M1 protein interactions with host factors is critical for novel therapeutic strategies.

Purpose of the Study:

  • To identify novel host proteins interacting with the IAV M1 protein.
  • To elucidate the functional role of PSMD12 in IAV replication.
  • To investigate the mechanism by which PSMD12 influences IAV assembly and release.

Main Methods:

  • Immunoprecipitation (IP) followed by mass spectrometry to identify M1-interacting proteins.
  • Site-directed mutagenesis to create M1-K102 mutant viruses.
  • Virus-like particle (VLP) assays, transmission electron microscopy, and mouse virulence studies.

Main Results:

  • PSMD12 was identified as a host factor interacting with IAV M1 protein.
  • PSMD12 promotes K63-linked ubiquitination of M1 at K102, enhancing viral replication and VLP release.
  • M1-K102 mutations or PSMD12 knockdown significantly impaired virus budding, VLP formation, and reduced virulence in mice.

Conclusions:

  • PSMD12 is a novel host factor that positively regulates IAV replication through M1 ubiquitination.
  • The M1-K102 ubiquitination site is critical for efficient virus assembly, budding, and virulence.
  • PSMD12 and the M1 ubiquitination pathway represent a promising target for anti-influenza drug development.